Innovent Biologics (09969) climbed more than 6% during early Hong Kong trading, with gains moderating to 5.24% at press time to HK$17.26. Trading volume reached HK$194 million. The biopharmaceutical firm announced that its self-developed novel BCL2 inhibitor mesutoclax (ICP-248), combined with azacitidine for treating myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), has received U.S. Food and Drug Administration (FDA) clearance for clinical studies. Public documentation indicates mesutoclax is a novel oral highly selective BCL2 inhibitor. BCL2 serves as a critical regulatory protein in cellular apoptosis pathways, with its abnormal expression linked to development of various hematological malignancies. By selectively inhibiting BCL2, mesutoclax reactivates programmed cell death mechanisms in tumor cells to exert anti-tumor effects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.